Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2949-2955

  Pircher, Andreas ^a   Ulsperger, Ernst ^c   Hack, Rene ^d   Jamnig, Herbert ^d   Pall, Georg ^a   Zelger, Bettina ^b   Sterlacci, William ^e   Hilbe, Wolfgang ^a   Fiegl, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c Hietzing Hospital   (Austria)

^d Natters Hospital   (Austria)

^e Academic Hospital Feldkirch   (Austria)

Author keywords

EAP; EGFR; Epidermal growth factor receptor; Expanded access programme; Gefitinib; Non small cell lung cancer; NSCLC; Skin toxicity

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PEMETREXED; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPONATREMIA; INFECTION; INTERSTITIAL PNEUMONIA; LIVER DISEASE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 80051649588     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
2. Auberger J, Loeffler-Ragg J, Wurzer W and Hilbe W: Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets 6: 271-294, 2006. (Pubitemid 43961864)
3. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
4. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22: 785-794, 2004. (Pubitemid 41103589)
5. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
6. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM and Douillard JY: Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
7. Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, Von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
8. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben Porat L, Memoli N, Zakowski M, Rusch V and Heelan RT: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22: 1103-1109, 2004. (Pubitemid 41095044)
9. Sequist LV, Bell DW, Lynch TJ and Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 25: 587-595, 2007.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
11. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Watkins CL, Duffield E, Armour AA and Mok T: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 27: 15s [abstr.8006]. 2009.
12. Fiegl M, Hilbe W, Auberger J, Schmid T, Aunerger T, Tzankov A, Sterlacci W, Denz H, Jamnig H and Greil R: Twelve-year retrospective analysis of lung cancer. The TYROL Study: Daily routine in 1,424 patients (1995-2006). J Clin Oncol 26: abstr 19063, 2008.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
14. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ and Johnson BE: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44: 221-230, 2004. (Pubitemid 38482055)
15. Reck M and Gatzemeier U: EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. Onkologie 28: 623-627, 2005. (Pubitemid 41759064)
16. Ochs J, Graus JJ and Warner KL: Final survival and safety results for 21,064 non-small cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). J Clin Oncol, 2004 ASCO Ann Meet Proc (Post-Meeting Edition) 22: (14S) 7060, 2004.
17. Pircher A, Ploner F, Popper H and Hilbe W: Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 69: 265-271, 2010.
18. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
19. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003. (Pubitemid 37432975)
20. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G and Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13: 3913-3921, 2007. (Pubitemid 47037599)